Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder
暂无分享,去创建一个
A. Serretti | P. Brambilla | M. Menchetti | P. Bozzatello | S. Bellino | P. Politi | M. Balestrieri | S. Porcelli | S. Pellegrini | C. Fabbri | V. Martinelli | C. Iofrida | V. Mariotti | E. Melissari | Y. Matsumoto | M. Cappucciati | E. Brignolo
[1] F. Fregni,et al. Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: Implications for the serotonergic system , 2013, European Neuropsychopharmacology.
[2] A. Serretti,et al. Pharmacogenetics in major depression: A comprehensive meta-analysis , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[3] D. Rujescu,et al. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression , 2013, European Archives of Psychiatry and Clinical Neuroscience.
[4] G. Andersson,et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta‐analysis of direct comparisons , 2013, World psychiatry : official journal of the World Psychiatric Association.
[5] L. Lazzeroni,et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression , 2013, Pharmacogenetics and genomics.
[6] A. Serretti,et al. No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression , 2013, Psychiatry investigation.
[7] R. Hen,et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities , 2013, Translational Psychiatry.
[8] S. Kaneko,et al. DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. , 2012, Journal of clinical psychopharmacology.
[9] Kangguang Lin,et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. , 2012, Psychiatric genetics.
[10] E. Frank,et al. The role of personality pathology in depression treatment outcome with psychotherapy and pharmacotherapy. , 2012, Journal of Consulting and Clinical Psychology.
[11] A. Serretti,et al. Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder , 2012, Psychiatry Research.
[12] J. Unützer,et al. Strategies to improve the management of depression in primary care. , 2012, Primary care.
[13] Evangelos Evangelou,et al. TPH2 Gene Polymorphisms and Major Depression – A Meta-Analysis , 2012, PloS one.
[14] A. Serretti,et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy , 2012, European Neuropsychopharmacology.
[15] F. Lohoff,et al. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. , 2012, Pharmacogenomics.
[16] Yonggui Yuan,et al. Tryptophan hydroxylase 2 gene is associated with major depressive disorder in a female Chinese population. , 2011, Journal of affective disorders.
[17] A. Serretti,et al. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia , 2011, Psychiatry Research.
[18] Edoardo Spina,et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism , 2011, Expert opinion on drug metabolism & toxicology.
[19] P. Deyn,et al. The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes , 2011, Psychiatry Research.
[20] R. Yoshimura,et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[21] R. Elliott,et al. The CREB1-BDNF-NTRK2 Pathway in Depression: Multiple Gene-Cognition-Environment Interactions , 2011, Biological Psychiatry.
[22] A. Serretti,et al. Pharmacogenetics of antidepressant response. , 2011, Journal of psychiatry & neuroscience : JPN.
[23] Y. Lecrubier,et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder , 2011, International clinical psychopharmacology.
[24] A. Serretti,et al. Pharmacogenetics of Antidepressants , 2010, Front. Pharmacol..
[25] S. Kim,et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression , 2010, Journal of psychopharmacology.
[26] P. Rucci,et al. Depression in Primary care: Interpersonal Counseling vs Selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design , 2010, BMC psychiatry.
[27] D. Ye,et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder , 2010, European Neuropsychopharmacology.
[28] C. Bouchard,et al. CREB1 Is a Strong Genetic Predictor of the Variation in Exercise Heart Rate Response to Regular Exercise: The HERITAGE Family Study , 2010, Circulation. Cardiovascular genetics.
[29] A. Serretti,et al. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.
[30] B. Franke,et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity , 2010, Molecular Psychiatry.
[31] N. Akarsu,et al. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels , 2010, Brain Research Bulletin.
[32] T. Vahlberg,et al. The outcomes of interpersonal counselling on depressive symptoms and distress after myocardial infarction , 2010, Nordic journal of psychiatry.
[33] V. Vaccarino,et al. Serotonin Transporter Gene, Depressive Symptoms, and Interleukin-6 , 2009, Circulation. Cardiovascular genetics.
[34] N. Wray,et al. Accurate, Large-Scale Genotyping of 5HTTLPR and Flanking Single Nucleotide Polymorphisms in an Association Study of Depression, Anxiety, and Personality Measures , 2009, Biological Psychiatry.
[35] T. Lehtimäki,et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression , 2009, Neuroreport.
[36] R. Yoshimura,et al. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[37] S. Tsai,et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[38] M. Wong,et al. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. , 2009, Archives of general psychiatry.
[39] J. Aldenhoff,et al. Changes in CREB Phosphorylation and BDNF Plasma Levels during Psychotherapy of Depression , 2009, Psychotherapy and Psychosomatics.
[40] F. McMahon,et al. Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. , 2009, The international journal of neuropsychopharmacology.
[41] D. Blackwood,et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy , 2009, The Pharmacogenomics Journal.
[42] J. Brockmöller,et al. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment , 2008, Pharmacogenetics and genomics.
[43] M. Åsberg,et al. The tryptophan hydroxylase (TPH) 2 gene unlike TPH-1 exhibits no association with stress-induced depression. , 2008, Journal of affective disorders.
[44] J. Mann,et al. No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. , 2008, Journal of affective disorders.
[45] G. Rosoklija,et al. Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression , 2008, Molecular Psychiatry.
[46] D. Blackwood,et al. A splice site polymorphism in the G-protein &bgr; subunit influences antidepressant efficacy in depression , 2007, Pharmacogenetics and genomics.
[47] K. Sleegers,et al. Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. , 2006, Archives of General Psychiatry.
[48] H. Corrêa,et al. Genotyping of the G1463A (Arg441His) TPH2 polymorphism in a geriatric population of patients with major depression , 2006, Molecular Psychiatry.
[49] T. Bourgeron,et al. No Human Tryptophan Hydroxylase-2 Gene R441H Mutation in a Large Cohort of Psychiatric Patients and Control Subjects , 2006, Biological Psychiatry.
[50] D. Goldman,et al. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. , 2005, Archives of general psychiatry.
[51] L. Marangell,et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance , 2005, Molecular Psychiatry.
[52] F. Taneli,et al. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[53] David A. Schwartz,et al. Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression , 2005, Neuron.
[54] H. Möller,et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression , 2004, Molecular Psychiatry.
[55] J. Knowles,et al. Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.
[56] F. Mazzi,et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.
[57] S. Tsai,et al. Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[58] M. Egan,et al. The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.
[59] J. Aldenhoff,et al. Changes in CREB-phosphorylation during recovery from major depression. , 2002, Journal of psychiatric research.
[60] D. Ginty,et al. Function and Regulation of CREB Family Transcription Factors in the Nervous System , 2002, Neuron.
[61] G. Zubenko,et al. Genome survey for susceptibility loci for recurrent, early-onset major depression: results at 10cM resolution. , 2002, American journal of medical genetics.
[62] P. Zwanzger,et al. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression , 2001, European Neuropsychopharmacology.
[63] Marc Montminy,et al. Transcriptional regulation by the phosphorylation-dependent factor CREB , 2001, Nature Reviews Molecular Cell Biology.
[64] M. Weissman,et al. A comparative study of venlafaxine with a focused education and psychotherapy program versus venlafaxine alone in the treatment of depression in general practice , 2001, Human psychopharmacology.
[65] H. Vedder,et al. Cytokine Production and Treatment Response in Major Depressive Disorder , 2000, Neuropsychopharmacology.
[66] M. Takigawa,et al. Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission , 1999, Biological Psychiatry.
[67] H. Manji,et al. A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization , 1997, Journal of neurochemistry.
[68] Paul J. Harrison,et al. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain , 1995, Brain Research.
[69] A. Serretti,et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. , 2011, Journal of affective disorders.
[70] J. Bauer,et al. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission , 2008, European Archives of Psychiatry and Clinical Neuroscience.
[71] B. Lebowitz,et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.
[72] I. Kusumi,et al. Serotonin-induced platelet intracellular calcium mobilization in depressed patients , 2005, Psychopharmacology.
[73] G. Zubenko,et al. D2S2944 identifies a likely susceptibility locus for recurrent, early-onset, major depression in women , 2002, Molecular Psychiatry.